Renopharma

Renopharma is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic kidney disease (CKD) and its associated complications. The company's primary focus lies in nephrology, with a pipeline featuring small molecule therapeutics designed to manage renal anemia and hyperphosphatemia. Its lead candidate, REN001, is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor currently in late-stage clinical development for the treatment of anemia in patients with CKD. Renopharma aims to address the significant unmet medical needs of the global CKD patient population through its specialized research and development efforts. The company is headquartered in Suzhou, China, and has received significant backing from prominent life science investors including Lilly Asia Ventures and Qiming Venture Partners.